Cardiff Oncology Inc. (CRDF)
Company Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California.
Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.
The company primarily serves pharmaceutical manufacturers.
The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.
Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| Country | United States |
| IPO Date | Jul 27, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Dr. Mark Erlander Ph.D. |
Contact Details
Address: 11055 Flintkote Avenue San Diego, California United States | |
| Website | https://www.cardiffoncology.com |
Stock Details
| Ticker Symbol | CRDF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001213037 |
| CUSIP Number | 14147L108 |
| ISIN Number | US14147L1089 |
| Employer ID | 27-2004382 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Erlander Ph.D. | Chief Executive Officer & Director |
| James E. Levine | Chief Financial Officer |
| Brigitte Lindsay | Senior Vice President of Finance |
| Charles Monahan R.Ph. | Senior Vice President of Regulatory Affairs |
| Dr. Fairooz F. Kabbinavar FACP, M.D. | Chief Medical Officer |
| Dr. Tod Smeal Ph.D. | Chief Scientific Officer |
| Elizabeth Anderson | Vice President of Finance & Administration |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2025 | 4 | Filing |
| Mar 13, 2025 | 4 | Filing |
| Mar 13, 2025 | 4 | Filing |
| Mar 13, 2025 | 4 | Filing |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 27, 2025 | S-3 | Filing |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 05, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 06, 2025 | 8-K | Current Report |